- Current report filing (8-K)
June 10 2010 - 5:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
June 7, 2010
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification
No.)
|
incorporation)
|
|
|
|
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices)
(425) 354-5038
Registrants telephone number, including area code
(Former name or former address,
if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item
5.07 Submission of Matters to a Vote of Security Holders.
On June 7, 2010, AVI BioPharma, Inc. (the Company)
held its 2010 Annual Meeting of the shareholders
(the Annual Meeting) at which the shareholders voted upon (i) the
re-election of Mr. William Goolsbee and Dr. Gil Price as Class I
directors and the election of Mr. Chris Garabedian and Dr. Hans
Wigzell as Class I directors to the Companys Board of Directors, each for
a two-year term, and (ii) ratification of the appointment of KPMG LLP as
independent registered public accounting firm for the fiscal year ending December 31,
2010.
The shareholders elected each of the directors and
director nominees and approved the ratification of the appointment of KPMG LLP
as independent registered public accounting firm for the fiscal year ending December 31,
2010.
The Company had 110,374,160 shares of Common Stock
outstanding as of March 31, 2010, the record date for the Annual Meeting.
At the Annual Meeting, holders of a total of 81,408,835 (73.76%) shares of
Common Stock were present in person or represented by proxy. The following sets
forth information regarding the results of the voting at the Annual Meeting:
Proposal 1
: The
shareholders voted to elect the following individuals as Class I directors
for a two-year term as follows:
Nominees
|
|
For
|
|
Withheld
|
|
Broker Non-Votes
|
|
|
|
|
|
|
|
|
|
Mr. William Goolsbee
|
|
29,468,820
|
|
1,362,644
|
|
50,577,371
|
|
|
|
|
|
|
|
|
|
Dr. Gil Price
|
|
29,817,292
|
|
1,014,172
|
|
50,577,371
|
|
|
|
|
|
|
|
|
|
Dr. Hans Wigzell
|
|
30,287,239
|
|
544,225
|
|
50,577,371
|
|
|
|
|
|
|
|
|
|
Mr. Chris Garabedian
|
|
29,536,692
|
|
1,294,772
|
|
50,577,371
|
|
Proposal 2
: A
proposal to approve KPMG LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2010 was adopted
with the votes shown:
For
|
|
Against
|
|
Abstain
|
|
|
|
|
|
|
|
79,498,694
|
|
1,682,461
|
|
227,680
|
|
Item
8.01 Other Events.
Following the Annual Meeting, the Companys Board of
Directors appointed Mr. William Goolsbee Chairman of the Board of
Directors.
2
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City
of Bothell, State of Washington, on June 10, 2010.
|
AVI
BioPharma, Inc.
|
|
|
|
By:
|
/s/ J. David Boyle II
|
|
|
|
|
|
J. David Boyle II
|
|
|
Interim
President and Chief Executive Officer, and Senior Vice President and Chief
Financial Officer
|
3
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024